Amarin Corp. (AMRN) recently reported their Q4 2019 earnings with a strong beat on EPS and revenue. The company's flagship product, Vascepa, continues to establish a market by becoming an important tool in the battle against cardiovascular disease. Unfortunately, Amarin released its earnings in the middle of the Coronavirus Crash and the stock has nosedived to 52-week lows.
In my previous article, I discussed how I "sold a large portion of my position upon approval and quickly employed some put options for insurance just in case the sellers really want to chop